Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 24;7(35):30978-30988.
doi: 10.1021/acsomega.2c02966. eCollection 2022 Sep 6.

Pyridine-Based NNS Tridentate Chitosan Thiosemicarbazones and Their Copper(II) Complexes: Synthesis, Characterization, and Anticancer Activity

Affiliations

Pyridine-Based NNS Tridentate Chitosan Thiosemicarbazones and Their Copper(II) Complexes: Synthesis, Characterization, and Anticancer Activity

Hari Sharan Adhikari et al. ACS Omega. .

Abstract

Chitosan-functionalized pyridine-based thiosemicarbazones and their copper(II) complexes have been found to own a substantial antiproliferative activity against the tumorigenic Madin Darby canine kidney (MDCK) and MCF-7 cancer cell lines. In the current study, chitosan oligosaccharide (CS) (87% DDA, Mw < 3000 Da) and crab shell chitosan (CCS) (67% DDA, M w 350 kDa) were functionalized as chitosan pyridine-2-thiosemicarbazones and chitosan 2-acetyl pyridine-2-thiosemicarbazones, and their copper(II) complexes were synthesized. The formation of chitosan thiosemicarbazones and their NNS tridentate behavior to give the square planar copper(II) chitosan thiosemicarbazone complexes were established by spectroscopic studies, powder X-ray diffraction, elemental analysis, and magnetic moment measurements. The thermal study showed a marked stability of these derivatives before the outset of chitosan backbone degradation at 200 °C. The colorimetric MTT assay revealed a higher activity of CS thiosemicarbazones, viz., CSTSC series (IC50 375-381 μg mL-1 in the MDCK cell line and 281-355 μg mL-1 in the MCF-7 cell line) than that of high-molecular-weight CCS thiosemicarbazones, viz., CCSTSC series (IC50 335-400 μg mL-1 in the MDCK cell line and 365-400 μg mL-1 in the MCF-7 cell line), showing an enhanced activity with a decrease in Mw and an increase in DDA of constituent chitosan, a higher activity of both of these series of thiosemicarbazones than that of their native chitosan, viz., CS (IC50 370 μg mL-1 in the MCF-7 cell line and >400 μg mL-1 in the MDCK cell line) and CCS (IC50 > 400 μg mL-1 in both cell lines), and a higher activity of the Cu-CSTSC complexes (IC50 322-342 μg mL-1 in the MDCK cell line and 278-352 μg mL-1 in the MCF-7 cell line) and Cu-CCSTSC complexes (IC50 274-400 μg mL-1 in the MDCK cell line and 231-352 μg mL-1 in the MCF-7 cell line) than that of their respective ligands.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Synthetic route of chitosan TSCs via the formation of the chitosan thiosemicarbazide intermediate.
Figure 2
Figure 2
Proposed structure of complexes: (a). Cu-CSPCTSC and Cu-CCSPCTSC. (b). Cu-CSAPRTSC and Cu-CCSAPRTSC.

References

    1. Wimardhani Y. S.; Suniarti D. F.; Freisleben H. J.; Wanandi S. I.; Ikeda M. A. Cytotoxic effects of chitosan against oral cancer cell lines is molecular-weight-dependent and cell type-specific. Int. J. Oral Res. 2012, 3, 1–10.
    1. Adhikari H. S.; Yadav P. N. Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action. Int. J. Biomater. 2018, 2018, 2952085. 10.1155/2018/2952085. - DOI - PMC - PubMed
    1. Gavhane Y. N.; Gurav A. S.; Yadav A. V. Chitosan and Its Applications: A Review of Literature. Int. J. Res. Pharm. Biomed. Sci. 2013, 4, 312–331.
    1. Zhang H.; Wu F.; Li Y.; Yang X.; Huang J.; Lv T.; Zhang Y.; Chen J.; Chen H.; Gao Y.; Liu G.; Jia L. Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone. Beilstein J. Nanotechnol. 2016, 7, 1861–1870. 10.3762/bjnano.7.178. - DOI - PMC - PubMed
    1. Thanou M.; Verhoef J. C.; Junginger H. E. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Delivery Rev. 2001, 50, S91–S101. 10.1016/s0169-409x(01)00180-6. - DOI - PubMed